Downregulation of Glutamic-oxaloacetic transaminase 2 (GOT2) in HCC is associated with advanced disease stages and poor patient outcomes, signifying its potential as a prognostic marker. This evidence concerns the gene GOT2 and hepatocellular carcinoma.